Compare Amphastar Pharmaceuticals Inc (AMPH) vs Carnival Corp (CCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Carnival Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Carnival Corp trades at $27.75 (market cap $39.71B). The key difference: Carnival Corp is far larger — about 46× Amphastar Pharmaceuticals Inc's market cap, and Carnival Corp pays a 1.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CCL | |
|---|---|---|
Market Cap | $863.95M | $39.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $33.99 |
52-Week Low | $16.87 | $23.89 |
Enterprise Value | $1.26B | $63.63B |
Dividend Yield | — | 1.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Carnival Corporation (CCL) trades at $28.99, up 0.69% today, with a bullish technical signal from moving averages and strong support at $28. The stock shows robust fundamentals, with revenue growing to $26.62B in 2025 and net income at $2.76B, while recent quarters have beaten EPS estimates. Analysts maintain a buy consensus with a $35.18 price target, and positive news highlights fleet expansion and sustainability initiatives.
The outlook for CCL is positive, driven by record travel demand, cost control, and debt reduction, offering potential upside to the consensus target. Risks include fuel price volatility, economic sensitivity, and high leverage, though improved cash flow and dividend reinstatement support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
